[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100590721":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":18,"centralContacts":36,"locations":41,"responsibleParty":62,"collaborators":10,"id":64,"slug":65,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":10,"eligibilityCriteria":70,"healthyVolunteers":66,"sex":71,"minAge":72,"maxAge":10,"enrollmentInfo":73,"targetDuration":10,"studyType":76,"phases":10,"briefSummary":77,"conditions":78,"keywords":82,"overallStatus":90,"whyStopped":10,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":100},{"fullName":5,"class":6},"Turkish Society of Colon and Rectal Surgery","OTHER",[8,12,15],{"label":9,"type":10,"description":11,"interventionNames":10},"MLH1\u002FPMS2 loss group",null,"Participants whose tumors show loss of MLH1 and PMS2 protein expression, typically associated with dMMR or MLH1 promoter hypermethylation. These tumors will be analyzed for clinical features and oncologic outcomes (DFS and OS) over 3 years.",{"label":13,"type":10,"description":14,"interventionNames":10},"MSH2\u002FMSH6 Loss Group","Participants whose tumors show loss of MSH2 and MSH6 protein expression. This pattern is commonly associated with Lynch syndrome, a hereditary form of mismatch repair deficiency. Prognostic and treatment outcome data will be analyzed.",{"label":16,"type":10,"description":17,"interventionNames":10},"Sporadic Group (pMMR)","Participants with no loss of MMR protein expression (proficient MMR; pMMR). These cases represent sporadic tumors without mismatch repair deficiency and will serve as a comparison group for evaluating oncologic outcomes.",[19,23,27,31,33],{"name":20,"affiliation":21,"role":22},"Ahmet Rencüzoğulları, Professor","Koç University","STUDY_DIRECTOR",{"name":24,"affiliation":25,"role":26},"Mustafa Öncel, Professor","İstanbul Medipol University","STUDY_CHAIR",{"name":28,"affiliation":29,"role":30},"Burak Yavuz, M.D.","Republic of Türkiye Ministry of Health Kozan State Hospital","PRINCIPAL_INVESTIGATOR",{"name":32,"affiliation":25,"role":30},"Atıf Tekin, M.D.",{"name":34,"affiliation":35,"role":26},"Cihangir Akyol, Professor","Ankara University",[37],{"name":20,"role":38,"phone":39,"phoneExt":10,"email":40},"CONTACT","+90 532 179 82 80","arencuzogullari@ku.edu.tr",[42,56],{"facility":25,"status":10,"city":43,"state":10,"zip":10,"country":44,"countryCode":10,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"Istanbul","Turkey (Türkiye)",{"type":46,"coordinates":47},"Point",[48,49],28.94966,41.01384,{"lat":49,"lon":48},[52],{"name":53,"role":38,"phone":54,"phoneExt":10,"email":55},"Atıf Tekin, Assistant Professor","+902124447044","atiftekin@medipol.edu.tr",{"facility":21,"status":10,"city":43,"state":10,"zip":10,"country":44,"countryCode":10,"cosmosGeoPoint":57,"geoPoint":59,"contacts":60},{"type":46,"coordinates":58},[48,49],{"lat":49,"lon":48},[61],{"name":20,"role":38,"phone":39,"phoneExt":10,"email":40},{"type":63,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100590721","current-microsatellite-stability-results-in-colon-cancer-100590721",false,"NCT06971107","Current Microsatellite Stability Results in Colon Cancer","TKRCD-MSI Study: Current Microsatellite Stability Findings in Colon Cancer - Nationwide Experience From Turkey","Inclusion Criteria:\n\nPatients who have undergone curative-intent surgery for colon adenocarcinoma between June 1, 2025, and May 31, 2026 Surgery performed at a center with \\>30 colon cancer surgeries per year Availability of MMR protein immunohistochemistry (IHC) and\u002For MSI test results from resection specimen and\u002For preoperative endoscopic biopsy Signed informed consent for participation and data collection\n\nExclusion Criteria:\n\nNon-adenocarcinoma malignancies of the colon (e.g., neuroendocrine tumors, lymphomas) Rectal cancers (defined as tumors within 15 cm of the anal verge on endoscopy or MRI) Incomplete medical or pathological records preventing classification of MMR status","ALL","18 Years",{"count":74,"type":75},1500,"ESTIMATED","OBSERVATIONAL","The goal of this prospective observational study is to learn more about how a specific type of DNA repair issue-called mismatch repair deficiency (dMMR)-affects colon cancer in people living in Turkey. The study will look at how often dMMR occurs, how it is reported, and how it relates to treatment outcomes.\n\nThe main questions it aims to answer are:\n\n* How common is dMMR in colon cancer, and does it vary by where the tumor is in the colon?\n* How often is MSI (microsatellite instability) status reported in colon cancer biopsy reports before surgery?\n* How do different types of dMMR (such as MLH1\u002FPMS2 loss, MSH2\u002FMSH6 loss, or sporadic cases) affect survival over three years?\n\nParticipants will:\n\n* Be people who had surgery for colon cancer between June 1, 2025 and May 31, 2026 at hospitals in Turkey that treat more than 30 colon cancer cases each year.\n* Have their medical and pathology data reviewed, including information about tumor location, biopsy results, surgery, and treatment.\n\nThis study will not involve any new treatments. Instead, it will use existing medical records to better understand how to improve care and identify people who may benefit from immunotherapy. Results from this study will be shared at scientific meetings and published in medical journals.",[79,80,81],"Colon Adenocarcinoma","MSI Positive Colorectal Cancer","MSI Negative Colorectal Cancer",[83,84,85,86,87,88,89],"Colorectal Neoplasms","Microstaellite Instability","DNA Mismatch Repair","Immunohistochemistry","Prognosis","Survival Analysis","Epidemiologic Methods","NOT_YET_RECRUITING","2025-05-06",{"date":93,"type":94},"2025-05-14","ACTUAL",{"date":96,"type":75},"2025-06-01",{"date":98,"type":75},"2029-05-31",{"name":5,"class":6},2]